Patrick Vermersch News Today

Frexalimab demonstrated a favorable tolerability profile after approximately 1 year of treatment for individuals with relapsing disease.

Patrick Vermersch, MD, PhD, University of Lille, France details the adverse events observed in the frexalimab trials and the next steps necessary to establish frexalimab as a standard of care in multiple sclerosis (MS) in the third and final part of an interview.

PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM...

Sanofi announces that the New England Journal of Medicine has published positive results from a Phase II trial showing that frexalimab significantly slowed disease activity in people with...

Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MSHigh-dose frexalimab significantly reduced dis...

Generally favorable effect seen in terms of number of new gadolinium-enhancing T1-weighted lesions at week 12.

Frexalimab shows promise in phase II study

Novel agent led to sustained reduction of new lesions at 24 weeks

CD40 ligand inhibitor leads to sustained reduction of MRI disease activity

Ad Scientiam Launches International Study to Assess Disability Progression ...